Nucleus is linking DNA to health outcomes.
The latest: The genomics startup secured $14M in a Series A led by Seven Seven Six and Founders Fund, bringing total funding to $32M.
Decoded. Streamlining 70K+ genetic tests into one, Nucleus aims to make clinical-grade DNA insights widely accessible.
For $399, consumers receive comprehensive genetic health analysis through an at-home cheek swab — screening for risk of major conditions like heart disease, cancer, and Alzheimer’s.
Growth mode. Ramping up, its user base tripled since last fall, with revenue climbing 68% MoM while expanding genetic analysis capabilities from 10 to 800+ conditions.
Alongside new capital, Nucleus announced the acquisition of AI platform Cambrean, combining DNA insights with wearable data to deliver personalized recommendations.
Bringing whole-genome sequencing into standard care practices, it’s also kicking off clinical partnerships starting with preventative health platform Bionic Health.
Looking ahead: Building an integrated platform, Nucleus aims to make genome sequencing as foundational as blood tests. Scaling beyond DTC tests, delivering better health outcomes is the next proof point.
